Piper Sandler analyst Yasmeen Rahimi assigned a Buy rating to Immunic (IMUX – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $1.57.
Rahimi covers the Healthcare sector, focusing on stocks such as Prothena, CymaBay Therapeutics, and Ventyx Biosciences. According to TipRanks, Rahimi has an average return of 10.5% and a 38.61% success rate on recommended stocks.
In addition to Piper Sandler, Immunic also received a Buy from Wedbush’s Andreas Argyrides in a report issued on April 6. However, on April 5, SVB Securities reiterated a Hold rating on Immunic (NASDAQ: IMUX).
See the top stocks recommended by analysts >>
IMUX market cap is currently $72.82M and has a P/E ratio of -0.41.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
Read More on IMUX:
